Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TraSki: Effects of Tralokinumab treatment on skin barrier function in atopic dermatitis
2019-000598-22Phase 2Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tralokinumab in atopic dermatitis (AD), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: Change in transepidermal water loss at week 16 in non-lesional and lesional skin. Started Apr 2020; status: completed.
02
Drugs
tralokinumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2019-000598-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000598-22.